109 related articles for article (PubMed ID: 21362795)
21. [Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society].
Salvarani C; Olivieri I; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M
Reumatismo; 2004; 56(3):133-4, 136-8. PubMed ID: 15470517
[No Abstract] [Full Text] [Related]
22. Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-alpha therapy in a patient with psoriatic arthritis and psoriasis vulgaris.
Antoniou C; Dessinioti C; Katsambas A; Stratigos AJ
Br J Dermatol; 2007 May; 156(5):1090-1. PubMed ID: 17408391
[No Abstract] [Full Text] [Related]
23. Report of an additional case of anti-tumor necrosis factor therapy and Listeria monocytogenes infection: comment on the letter by Glück et al.
Aparicio AG; Muñoz-Fernández S; Bonilla G; Miralles A; Cerdeño V; Martín-Mola E
Arthritis Rheum; 2003 Jun; 48(6):1764-5; author reply 1765-6. PubMed ID: 12794847
[No Abstract] [Full Text] [Related]
24. Do TNF-blockers reduce or induce uveitis?
Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E
Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
[No Abstract] [Full Text] [Related]
25. [Innovative therapeutic options for psoriatic arthritis: TNFalpha inhibitors].
Lehnen M; Goos M; Dissemond J
Dtsch Med Wochenschr; 2004 Mar; 129(12):634-8. PubMed ID: 15011134
[No Abstract] [Full Text] [Related]
26. Interstitial pneumonitis and anti-tumor necrosis factor-alpha therapy.
Roos JC; Chilvers ER; Ostor AJ
J Rheumatol; 2007 Jan; 34(1):238-9; author reply 239. PubMed ID: 17216703
[No Abstract] [Full Text] [Related]
27. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
Goodemote P; Jamieson B; Hoffman R
J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
[No Abstract] [Full Text] [Related]
28. [TNF-alpha inhibitors].
Fain O
Rev Prat; 2003 Nov; 53(18):1989-90. PubMed ID: 15008210
[No Abstract] [Full Text] [Related]
29. Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors.
Exarchou SA; Voulgari PV; Markatseli TE; Zioga A; Drosos AA
Scand J Rheumatol; 2009; 38(5):328-31. PubMed ID: 19579151
[TBL] [Abstract][Full Text] [Related]
30. Erythema multiforme with tumour necrosis factor inhibitors: a class effect?
Kain T; MacGregor D; Buchanan RR; de Jager JP; Schachna L
Ann Rheum Dis; 2008 Jun; 67(6):899-900. PubMed ID: 18474663
[No Abstract] [Full Text] [Related]
31. [The off-label-prescription of TNF-alpha blocking agents for spondyloarthropathies in the context of recent statement by a German federal court].
Sieper J
Z Rheumatol; 2002 Dec; 61(6):688-93. PubMed ID: 12491132
[TBL] [Abstract][Full Text] [Related]
32. Mycobacterial hand infections occurring postoperatively in patients treated with tumor necrosis factor-alpha inhibitors for inflammatory arthritis: report of three cases.
Bauer AS; Blazar PE; Earp BE; Simmons BP
J Hand Surg Am; 2010 Jan; 35(1):104-8. PubMed ID: 20117311
[TBL] [Abstract][Full Text] [Related]
33. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
34. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
Delaunay C; Farrenq V; Marini-Portugal A; Cohen JD; Chevalier X; Claudepierre P
J Rheumatol; 2005 Nov; 32(11):2183-5. PubMed ID: 16265699
[TBL] [Abstract][Full Text] [Related]
35. Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy.
Taylor JC; Orkin R; Lanham J
Rheumatology (Oxford); 2003 Jul; 42(7):901-2. PubMed ID: 12826707
[No Abstract] [Full Text] [Related]
36. Chest pain as presenting symptom of Staphyloccocus aureus epidural abscess associated with anti-tumor necrosis factor and methotrexate therapy.
Vasoo S; Gurnani P; Agustin T; Lee J; Singh K
J Clin Rheumatol; 2009 Dec; 15(8):396-8. PubMed ID: 19955997
[TBL] [Abstract][Full Text] [Related]
37. Infliximab in patients with systemic vasculitis that is difficult to treat: poor outcome and significant adverse effects.
Sangle SR; Hughes GR; D'Cruz DP
Ann Rheum Dis; 2007 Apr; 66(4):564-5. PubMed ID: 17360788
[No Abstract] [Full Text] [Related]
38. Tumor necrosis factor-alpha blocker induced tuberculosis.
Kharbanda P; Dagaonkar R; Balakrishnan C; Udwadia ZF
J Rheumatol; 2010 Jul; 37(7):1542; author reply 1543. PubMed ID: 20595292
[No Abstract] [Full Text] [Related]
39. Rheumatoid vasculitis treated with infliximab.
van der Bijl AE; Allaart CF; Van Vugt J; Van Duinen S; Breedveld FC
J Rheumatol; 2005 Aug; 32(8):1607-9. PubMed ID: 16078342
[TBL] [Abstract][Full Text] [Related]
40. Intra-articular infliximab in patients with rheumatoid arthritis and psoriatic arthritis with monoarthritis resistant to local glucocorticoids. Clinical efficacy extended to patients on systemic anti-tumour necrosis factor alpha.
Conti F; Ceccarelli F; Priori R; Iagnocco A; Signore A; Valesini G
Ann Rheum Dis; 2008 Dec; 67(12):1787-90. PubMed ID: 19005158
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
